PETMED EXPRESS INC
Business
PetMed Express, Inc. operates PetMeds and PetCareRx, direct-to-consumer online pet pharmacies selling prescription medications, over-the-counter health products, pet food, and wellness supplies for dogs, cats, and horses. The company sources inventory from pharmaceutical manufacturers and distributors, operates licensed pharmacies in Florida and New York, and fulfills orders nationwide after veterinary prescription verification. PetMeds serves the U.S. pet healthcare market through e-commerce, mobile apps, customer contact centers, and employer benefits partnerships.
Summary from 10-K filed 2026-06-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Net sales | 179 | 227 | 274 | 248 | — | |
| Cost of sales | 127 | 158 | 189 | — | — | |
| Inventory write-down | 2 | 0 | 0 | — | — | |
| Gross profit | 50 | 69 | 85 | 77 | 77 | |
| General and administrative | 51 | 39 | 55 | 42 | 31 | |
| Advertising | 22 | 24 | 31 | 25 | 19 | |
| Depreciation and amortization | 9 | 7 | 7 | 4 | 3 | |
| Impairment of goodwill and intangible assets | 27 | 1 | 0 | 0 | — | |
| Total operating expenses | 109 | 71 | 93 | 70 | 53 | |
| Loss from operations | −59 | −2 | −8 | 6 | 24 | |
| Interest income (expense), net | 511,000 | 185,000 | 511,000 | 450,000 | — | |
| Other, net | 803,000 | 758,000 | 1 | 944,000 | 1 | |
| Total other income (expense) | 1 | 943,000 | 2 | 1 | −105,000 | |
| (Loss) income before provision for income taxes | −57 | −587,000 | −6 | 7 | 24 | |
| (Benefit) provision for income taxes | −73,000 | 6 | 1 | 2 | 5 | |
| Net loss | −57 | −6 | −7 | 5 | 19 | |
| Basic (in dollars per share) | −2.74 | −0.3 | −0.37 | 0.25 | 0.93 | |
| Diluted (in dollars per share) | −2.74 | −0.3 | −0.37 | 0.25 | 0.92 | |
| Basic (in shares) | 21 | 21 | 20 | 20 | 20 | |
| Diluted (in shares) | 21 | 21 | 20 | 20 | 20 | |
| Cash dividends declared per common share (in dollars per share) | 0 | 0 | 0.6 | 1.2 | 1.2 |
Consolidated Balance Sheet
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 21 | 55 | 55 | 104 | 111 | |
| Accounts receivable, less allowance for credit losses of $25 and $91, respectively | 2 | 2 | 3 | 2 | 2 | |
| Inventories, net | 14 | 16 | 29 | — | — | |
| Prepaid expenses and other current assets | 6 | 5 | 6 | 5 | 5 | |
| Prepaid income taxes | 258,000 | 299,000 | 188,000 | 863,000 | 681,000 | |
| Total current assets | 44 | 79 | 94 | 130 | 151 | |
| Property and equipment, net | 26 | 29 | 27 | 26 | 24 | |
| Intangible and other assets, net | 11 | 13 | 17 | 6 | — | |
| Goodwill | 0 | 27 | 27 | 0 | — | |
| Operating lease right-of-use assets, net | 512,000 | 966,000 | 1 | 0 | — | |
| Total noncurrent assets | 38 | 70 | 76 | 37 | 25 | |
| Total assets | 81 | 149 | 170 | 167 | 176 | |
| Accounts payable | 21 | 24 | 37 | 25 | 28 | |
| Sales tax payable | 22 | 25 | 25 | 26 | — | |
| Accrued expenses and other current liabilities | 8 | 12 | 7 | 6 | 6 | |
| Current operating lease liabilities | 493,000 | 461,000 | 459,000 | 0 | — | |
| Deferred revenue | 700,000 | 2 | 3 | 0 | — | |
| Income taxes payable | 20,000 | 80,000 | 0 | — | — | |
| Total current liabilities | 52 | 63 | 72 | 58 | 33 | |
| Deferred tax liabilities, net | 175,000 | 263,000 | 0 | 0 | 936,000 | |
| Long-term operating lease liabilities | 42,000 | 535,000 | 995,000 | 0 | — | |
| Total liabilities | 52 | 64 | 73 | 58 | 34 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Common stock, $.001 par value, 40,000,000 shares authorized; 21,385,638 and 20,656,822 shares issued and outstanding, respectively | 21,000 | 21,000 | 21,000 | 21,000 | 21,000 | |
| Additional paid-in capital | 20 | 19 | 25 | 18 | 12 | |
| Retained earnings | 9 | 67 | 72 | 92 | 130 | |
| Total shareholders' equity | 29 | 85 | 97 | 110 | 123 | |
| Total liabilities and shareholders' equity | 81 | 149 | 170 | 167 | 176 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2026 2026-03-31 | FY 2025 2025-03-31 | FY 2024 2024-03-31 | FY 2023 2023-03-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Share based compensation, net | 1 | −7 | 7 | 7 | 5 | |
| Deferred income taxes | −88,000 | 5 | 292,000 | −2 | −846,000 | |
| Bad debt (recovery) expense | −36,000 | 365,000 | 324,000 | 214,000 | 165,000 | |
| Change in sales tax liability estimation | −3 | 0 | 0 | — | — | |
| Accounts receivable | 445,000 | 601,000 | −2 | −41,000 | 509,000 | |
| Inventories | 471,000 | 12 | −6 | 13 | — | |
| Prepaid income taxes | 41,000 | −111,000 | 675,000 | −182,000 | 278,000 | |
| Prepaid expenses and other current assets | −1 | 995,000 | −185,000 | 147,000 | −363,000 | |
| Operating lease right-of-use assets, net | 454,000 | 466,000 | 788,000 | 0 | 0 | |
| Accounts payable | −3 | −13 | 6 | −2 | −12 | |
| Sales tax payable | 122,000 | −145,000 | −1 | 2 | 3 | |
| Accrued expenses and other current liabilities | −4 | 4 | 276,000 | 896,000 | −93,000 | |
| Operating lease liabilities | −461,000 | −458,000 | −766,000 | 0 | 0 | |
| Deferred revenue | −1 | −518,000 | −390,000 | 0 | 0 | |
| Income taxes payable | −60,000 | 80,000 | 0 | 0 | 0 | |
| Net cash (used in) provided by operating activities | −28 | 5 | 4 | 28 | 18 | |
| Purchase of minority interest investment in Vetster | 0 | 0 | −300,000 | −5 | 0 | |
| Acquisition of PetCareRx, net of cash acquired | 0 | 0 | −36 | 0 | 0 | |
| Purchases of property and equipment | −5 | −5 | −5 | −5 | −2 | |
| Net cash used in investing activities | −5 | −5 | −41 | −10 | −2 | |
| Dividends paid | −21,000 | −181,000 | −12 | −25 | −24 | |
| Cash paid for tax withholding on net settlement of restricted stock | −278,000 | 0 | 0 | — | — | |
| Net cash used in financing activities | −299,000 | −181,000 | −12 | −25 | −24 | |
| Net decrease in cash and cash equivalents | −33 | −576,000 | −49 | −7 | −8 | |
| Cash paid for income taxes | 52,000 | 525,000 | 130,000 | 4 | 6 | |
| Dividends payable in accrued expenses | 0 | 26,000 | 1 | 1 | 558,000 | |
| Non-cash investing activity for property and equipment additions | 282,000 | 2 | 0 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PETMED EXPRESS INC's CIK number?
PETMED EXPRESS INC's SEC CIK number is 0001040130 (1040130). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PETMED EXPRESS INC's SEC filings?
All of PETMED EXPRESS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PETMED EXPRESS INC last report earnings?
PETMED EXPRESS INC (PETS) most recently filed an earnings 8-K with the SEC on Jun 2, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001040130-26-000016). This is PETMED EXPRESS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is PETMED EXPRESS INC's most recent earnings 8-K?
PETMED EXPRESS INC's latest earnings 8-K (Item 2.02) was filed Jun 2, 2026 under accession 0001040130-26-000016. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PETMED EXPRESS INC's latest earnings 8-K →
Look up any company's CIK number →